- Home
- PAXS vs FLGT Comparison
PAXS vs FLGT Comparison
Compare PAXS & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAXS
- FLGT
- Stock Information
- Founded
- PAXS 2021
- FLGT 2011
- Country
- PAXS United States
- FLGT United States
- Employees
- PAXS N/A
- FLGT N/A
- Industry
- PAXS Investment Managers
- FLGT Medical Specialities
- Sector
- PAXS Finance
- FLGT Health Care
- Exchange
- PAXS Nasdaq
- FLGT Nasdaq
- Market Cap
- PAXS 677.7M
- FLGT 588.5M
- IPO Year
- PAXS N/A
- FLGT 2016
- Fundamental
- Price
- PAXS $15.09
- FLGT $19.37
- Analyst Decision
- PAXS
- FLGT Buy
- Analyst Count
- PAXS 0
- FLGT 2
- Target Price
- PAXS N/A
- FLGT $24.00
- AVG Volume (30 Days)
- PAXS 195.0K
- FLGT 206.2K
- Earning Date
- PAXS 01-01-0001
- FLGT 08-01-2025
- Dividend Yield
- PAXS 11.72%
- FLGT N/A
- EPS Growth
- PAXS N/A
- FLGT N/A
- EPS
- PAXS N/A
- FLGT N/A
- Revenue
- PAXS N/A
- FLGT $292,448,000.00
- Revenue This Year
- PAXS N/A
- FLGT $11.79
- Revenue Next Year
- PAXS N/A
- FLGT $10.45
- P/E Ratio
- PAXS N/A
- FLGT N/A
- Revenue Growth
- PAXS N/A
- FLGT 1.71
- 52 Week Low
- PAXS $12.57
- FLGT $14.57
- 52 Week High
- PAXS $15.93
- FLGT $25.11
- Technical
- Relative Strength Index (RSI)
- PAXS 49.31
- FLGT 41.40
- Support Level
- PAXS $15.05
- FLGT $19.18
- Resistance Level
- PAXS $15.19
- FLGT $19.96
- Average True Range (ATR)
- PAXS 0.09
- FLGT 0.50
- MACD
- PAXS 0.00
- FLGT -0.07
- Stochastic Oscillator
- PAXS 39.13
- FLGT 26.29
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.